Cosentyx (secukinumab) - Novartis
Cosentyx: Regulatory submission for pediatric psoriasis in 2019 (Novartis) - Dec 6, 2019 - R&D Day: Regulatory submission for psoriasis in 2020; Regulatory submission for spondyloarthritis in 2022; Regulatory submission for ankylosing spondylitis beyond 2023 
Regulatory
https://www.novartis.com/sites/www.novartis.com/files/2019-12-05-novartis-r-d-day-investor-presentation.pdf
 
Dec 6, 2019
 
 
8364c2f6-705e-44b5-bc1c-685169e6a636.jpg